You searched for "Ranibizumab"
Strategies for managing neovascular AMD and DMO in routine clinical care
1 October 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...
The natural history of treatment naïve choroidal neovascularisation (CNV) in geographic atrophy
1 February 2018
| Efrosini Papagiannuli
|
EYE - Vitreo-Retinal
The aim of this retrospective study is to assess the characteristics and natural history of quiescent CNV in geographic atrophy (GA) utilising multi-modal imaging. Case notes were reviewed of patients diagnosed with geographic atrophy between January 2010 and December 2016...
Outcomes of combined medial and laser treatment for advanced Coat’s disease
In this study, the anatomical and visual outcomes of paediatric patients with advanced stage 3+ Coat’s disease are reported. Patients were treated with a combination of intravitreal ranibizumab, laser photocoagulation and methyl prednisolone acetate. This was a retrospective review of...
RPE atrophy onset in treated nAMD
1 October 2019
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this study the authors aim to evaluate the role of various factors for the development of retinal pigment epithelium (RPE) atrophy over a period of five years in patients with nAMD. Fifty-two newly diagnosed nAMD patients with complete absence...
Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
1 February 2015
| Pearse A Keane (Prof), Adnan Tufail
|
EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
NICE drugs: an update on what’s good to go
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...
Outcomes of ‘treat and extend’ for neovascular AMD
1 August 2015
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
Stereotactic radiotherapy for polypoidal choroidal vasculopathy
1 August 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...
Retinal pigment epithelium tears
1 June 2016
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this paper the authors review the current knowledge of retinal pigment epithelium (RPE) tears. Although rare these can cause loss of visual acuity. They can occur spontaneously in pigment epithelial detachment (PED) due to occult choroidal neovascularisation (CNV), retinal...
Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...Treatment of diabetic macular oedema
1 June 2014
| Samantha S Mann
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
RaScaL Study
1 June 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
